Nano Dimension (TASE:NNDM,NASDAQ:NNDM), a leader in the field of 3D printed electronics, has supplied, in return for payment, its flagship DragonFly 2020 electronics 3D Printer to Syqe Medical Ltd. Syqe is the Tel Aviv-based developer of the world’s first selective-dose, pharmaceutical grade medical cannabis inhaler.

It uses 3D printers to prototype and produce inhalers, which have been used in Israel’s Rambam Hospital for more than a year. Syqe Medical joins the growing ranks of Nano Dimension’s beta clients, and plans to use Nano Dimension’s technology to further develop its inhalers.


 Nano Dimension’s beta program involves the delivery of the company’s DragonFly 2020 3D Printers to leading companies and partners worldwide through a leasing model. These customers are pioneering additive manufacturing technology and techniques for electronics and circuitry, and are active in a variety of industries, including: defense, consumer goods, technology for the finance industry and medical devices.

The customers will qualify the DragonFly 2020 technology and will use it to speed up their product development cycles. The DragonFly 2020 3D printer also allows them to strengthen their in-house innovation capabilities, while providing them with enhanced R&D IP security. In return, companies make payments on their leases and provide Nano Dimension with valuable feedback for further product development.

Nano Dimension, founded in 2012, focuses on development of advanced 3D printed electronics systems and advanced additive manufacturing. Nano Dimension’s unique products combine three advanced technologies: 3D inkjet, 3D software and nanomaterials.

The company’s primary products include the first 3D printer dedicated to printing multi-layer PCBs (printed circuit boards) and advanced nanotechnology-based conductive and dielectric inks. The company’s American Depositary Shares are traded on the NASDAQ, and its ordinary shares are also traded on the TASE in Israel. The Bank of New York Mellon serves as the depositary for Nano Dimension.

Syqe Medical is transforming cannabis and other plants into standard prescription medicines. The first plant the company enabled for use in its inhaler is medical cannabis. Syqe was founded in 2011. In 2013 Prof. Elon Eisenberg conducted the company’s first clinical trial at Rambam Healthcare Campus, in Haifa, which demonstrated the inhaler’s precision and compliance with pharmaceutical standards. In 2016, Syqe announced it had signed an agreement with Teva Pharmaceutical Industries Ltd., the world’s largest manufacturer of generic drugs, to market and distribute Syqe inhalers in Israel.

Trulieve Cannabis Corp. (“Trulieve” or the “Company”) (CSE: TRUL) (OTCQX: TCNNF), a leading and top-performing cannabis company in the United States today announced the appointment of Marcum LLP (“Marcum”) as its independent registered public accounting firm, effective July 5, 2021 . Marcum was appointed following the resignation of MNP LLP (“MNP”) as the Company’s independent registered public accounting firm effective July 5, 2021 .

“We would like to thank MNP for their guidance and expertise over the past two years and we look forward to working with Marcum as the Company’s new independent registered public accounting firm,” stated Chief Financial Officer, Alex D’Amico.

Keep reading... Show less

Cannabis-infused beverages are not a new product concept, but this summer Canadian drink makers hope consumers will discover them for the first time.

Recreational cannabis beverages have beguiled Canadian producers through different avenues, and many continue to make investments. The promise of these drinks lies in the potential of a more welcoming option for new consumers who may be out of their depth with rolled-up dried flower.

Keep reading... Show less

In the news release, BioHarvest Sciences Inc.‘s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years, issued 07-Jul-2021 by BioHarvest Sciences Inc. over PR Newswire, we are advised by the company that an incorrect version of the release was issued inadvertently. The complete, corrected release follows:

BioHarvest Sciences Inc.‘s First Cannabis Cell Reservoir Produces Ongoing Flowering Stage Cannabinoid Cells For 2 Years

Keep reading... Show less

Trulieve is the first medical cannabis operator to start planting in the state

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today that it commenced operations in West Virginia . The Company has begun cultivation at their 100,000 square foot size facility in Huntington, West Virginia .

Keep reading... Show less

– The Company demonstrates the efficiency and reliability of its BioFarming technology by reducing production cycle time for Cannabis from 14-23 weeks to 3-4 weeks.

– The Company’s BioFarming technology will allow the Company to harvest 13-17 cycles per year versus 2-4 cycles per year for conventional Cannabis agriculture.

Keep reading... Show less